期刊
TRANSPLANT INTERNATIONAL
卷 34, 期 10, 页码 1776-1788出版社
FRONTIERS MEDIA SA
DOI: 10.1111/tri.14029
关键词
immunogenicity; mRNA vaccine; organ transplantation; prevention; safety; SARS-CoV-2
资金
- ORCHESTRA project, Horizon 2020 research and innovation programme [101016167]
- Universite de Lausanne
SARS-CoV-2 vaccines provide important protection for SOT recipients, but antibody responses are decreased, and risk factors affecting immunogenicity should be noted, along with the need to continue personal protective measures. Prioritization of household contacts for vaccination after receiving the vaccine is recommended, while further research is needed for the evaluation of immune responses.
In response to the COVID-19 pandemic, SARS-CoV-2 vaccines have been developed at an unparalleled speed, with 14 SARS-CoV-2 vaccines currently authorized. Solid-organ transplant (SOT) recipients are at risk for developing a higher rate of COVID-19-related complications and therefore they are at priority for immunization against SARS-CoV-2. Preliminary data suggest that although SARS-CoV-2 vaccines are safe in SOT recipients (with similar rate of adverse events than in the general population), the antibody responses are decreased in this population. Risk factors for poor vaccine immunogenicity include older age, shorter time from transplantation, use of mycophenolate and belatacept, and worse allograft function. SOT recipients should continue to be advised to maintain hand hygiene, use of facemasks, and social distancing after SARS-CoV-2 vaccine. Vaccination of household contacts should be also prioritized. Although highly encouraged for research purposes, systematic assessment in clinical practice of humoral and cellular immune responses after SARS-CoV-2 vaccination is controversial, since correlation between immunological findings and clinical protection from severe COVID-19, and cutoffs for protection are currently unknown in SOT recipients. Alternative immunization schemes, including a booster dose, higher doses, and modulation of immunosuppression during vaccination, need to be assessed in the context of well-designed clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据